{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:31:14Z","timestamp":1794087074598,"version":"4.8.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011541","name":"U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA 240139"],"award-info":[{"award-number":["P30 CA 240139"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chromothripsis is detectable in 20\u201330% of newly diagnosed multiple myeloma (NDMM) patients and is emerging as a new independent adverse prognostic factor. In this study we interrogate 752 NDMM patients using whole genome sequencing (WGS) to investigate the relationship of copy number (CN) signatures to chromothripsis and show they are highly associated. CN signatures are highly predictive of the presence of chromothripsis (AUC\u2009=\u20090.90) and can be used identify its adverse prognostic impact. The ability of CN signatures to predict the presence of chromothripsis is confirmed in a validation series of WGS comprised of 235 hematological cancers (AUC\u2009=\u20090.97) and an independent series of 34 NDMM (AUC\u2009=\u20090.87). We show that CN signatures can also be derived from whole exome data (WES) and using 677 cases from the same series of NDMM, we are able to predict both the presence of chromothripsis (AUC\u2009=\u20090.82) and its adverse prognostic impact. CN signatures constitute a flexible tool to identify the presence of chromothripsis and is applicable to WES and WGS data.<\/jats:p>","DOI":"10.1038\/s41467-021-25469-8","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T06:03:36Z","timestamp":1630044216000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7873-4854","authenticated-orcid":false,"given":"Kylee H.","family":"Maclachlan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Even H.","family":"Rustad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2178-8493","authenticated-orcid":false,"given":"Andriy","family":"Derkach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binbin","family":"Zheng-Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata","family":"Yellapantula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8638-9365","authenticated-orcid":false,"given":"Benjamin","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9045-6495","authenticated-orcid":false,"given":"Malin","family":"Hultcrantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bachisio","family":"Ziccheddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen M.","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Blaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Bolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-5256","authenticated-orcid":false,"given":"Ahmet","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Lesokhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4271-6360","authenticated-orcid":false,"given":"Gareth J.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-4839","authenticated-orcid":false,"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5017-1620","authenticated-orcid":false,"given":"Francesco","family":"Maura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,27]]},"reference":[{"key":"25469_CR1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41588-019-0576-7","volume":"52","author":"I Cort\u00e9s-Ciriano","year":"2020","unstructured":"Cort\u00e9s-Ciriano, I. et al. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat. Genet. 52, 331\u2013341 (2020).","journal-title":"Nat. Genet."},{"key":"25469_CR2","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.cell.2013.02.023","volume":"152","author":"JO Korbel","year":"2013","unstructured":"Korbel, J. O. & Campbell, P. J. Criteria for inference of chromothripsis in cancer genomes. Cell 152, 1226\u20131236 (2013).","journal-title":"Cell"},{"key":"25469_CR3","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41588-020-0667-5","volume":"52","author":"J Maciejowski","year":"2020","unstructured":"Maciejowski, J. et al. APOBEC3-dependent kataegis and TREX1-driven chromothripsis during telomere crisis. Nat. Genet. 52, 884\u2013890 (2020).","journal-title":"Nat. Genet."},{"key":"25469_CR4","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1913-9","volume":"578","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. Patterns of somatic structural variation in human cancer genomes. Nature 578, 112\u2013121 (2020).","journal-title":"Nature"},{"key":"25469_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","volume":"578","author":"PJ Campbell","year":"2020","unstructured":"Campbell, P. J. et al. Pan-cancer analysis of whole genomes. Nature 578, 82\u201393 (2020).","journal-title":"Nature"},{"key":"25469_CR6","doi-asserted-by":"publisher","first-page":"eaba0712","DOI":"10.1126\/science.aba0712","volume":"368","author":"NT Umbreit","year":"2020","unstructured":"Umbreit, N. T. et al. Mechanisms generating cancer genome complexity from a single cell division error. Science 368, eaba0712 (2020).","journal-title":"Science"},{"key":"25469_CR7","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1182\/blood-2011-03-344069","volume":"118","author":"F Magrangeas","year":"2011","unstructured":"Magrangeas, F., Avet-Loiseau, H., Munshi, N. C. & Minvielle, S. Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients. Blood 118, 675\u2013678 (2011).","journal-title":"Blood"},{"key":"25469_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.cell.2020.08.006","volume":"183","author":"K Hadi","year":"2020","unstructured":"Hadi, K. et al. Distinct classes of complex structural variation uncovered across thousands of cancer genome graphs. Cell 183, 197\u2013210.e32 (2020).","journal-title":"Cell"},{"key":"25469_CR9","doi-asserted-by":"crossref","unstructured":"Rustad, E. H. et al. Revealing the impact of structural variants in multiple myeloma. Blood Cancer Discov. 1, 258\u2013273 (2020).","DOI":"10.1158\/2643-3230.BCD-20-0132"},{"key":"25469_CR10","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature14666","volume":"526","author":"XS Puente","year":"2015","unstructured":"Puente, X. S. et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature 526, 519\u2013524 (2015).","journal-title":"Nature"},{"key":"25469_CR11","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1053\/j.seminhematol.2013.10.001","volume":"50","author":"CG Mullighan","year":"2013","unstructured":"Mullighan, C. G. Genomic characterization of childhood acute lymphoblastic leukemia. Semin. Hematol. 50, 314\u2013324 (2013).","journal-title":"Semin. Hematol."},{"key":"25469_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22140-0","volume":"12","author":"B Oben","year":"2021","unstructured":"Oben, B. et al. Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Nat. Commun. 12, 1861 (2021).","journal-title":"Nat. Commun."},{"key":"25469_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05058-y","volume":"9","author":"N Bolli","year":"2018","unstructured":"Bolli, N. et al. Genomic patterns of progression in smoldering multiple myeloma. Nat. Commun. 9, 3363 (2018).","journal-title":"Nat. Commun."},{"key":"25469_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11680-1","volume":"10","author":"F Maura","year":"2019","unstructured":"Maura, F. et al. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat. Commun. 10, 3835 (2019).","journal-title":"Nat. Commun."},{"key":"25469_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17459-z","volume":"11","author":"HJ Landau","year":"2020","unstructured":"Landau, H. J. et al. Accelerated single cell seeding in relapsed multiple myeloma. Nat. Commun. 11, 3617 (2020).","journal-title":"Nat. Commun."},{"key":"25469_CR16","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ccell.2017.07.005","volume":"32","author":"LR Yates","year":"2017","unstructured":"Yates, L. R. et al. Genomic Evolution of Breast Cancer Metastasis and Relapse. Cancer Cell 32, 169\u2013184.e7 (2017).","journal-title":"Cancer Cell"},{"key":"25469_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16134-7","volume":"11","author":"N Voronina","year":"2020","unstructured":"Voronina, N. et al. The landscape of chromothripsis across adult cancer types. Nat. Commun. 11, 2320 (2020).","journal-title":"Nat. Commun."},{"key":"25469_CR18","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41588-018-0179-8","volume":"50","author":"G Macintyre","year":"2018","unstructured":"Macintyre, G. et al. Copy number signatures and mutational processes in ovarian carcinoma. Nat. Genet. 50, 1262\u20131270 (2018).","journal-title":"Nat. Genet."},{"key":"25469_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature17676","volume":"534","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47\u201354 (2016).","journal-title":"Nature"},{"key":"25469_CR20","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","volume":"132","author":"BA Walker","year":"2018","unstructured":"Walker, B. A. et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood 132, 587\u2013597 (2018).","journal-title":"Blood"},{"key":"25469_CR21","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/bioinformatics\/btr670","volume":"28","author":"V Boeva","year":"2012","unstructured":"Boeva, V. et al. Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics 28, 423\u2013425 (2012).","journal-title":"Bioinformatics"},{"key":"25469_CR22","doi-asserted-by":"publisher","first-page":"i333","DOI":"10.1093\/bioinformatics\/bts378","volume":"28","author":"T Rausch","year":"2012","unstructured":"Rausch, T. et al. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics 28, i333\u2013i339 (2012).","journal-title":"Bioinformatics"},{"key":"25469_CR23","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/bioinformatics\/btv710","volume":"32","author":"X Chen","year":"2015","unstructured":"Chen, X. et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics 32, 1220\u20131222 (2015).","journal-title":"Bioinformatics"},{"key":"25469_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7997","volume":"6","author":"BA Walker","year":"2015","unstructured":"Walker, B. A. et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat. Commun. 6, 6997 (2015).","journal-title":"Nat. Commun."},{"key":"25469_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","volume":"33","author":"BA Walker","year":"2019","unstructured":"Walker, B. A. et al. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia 33, 159\u2013170 (2019).","journal-title":"Leukemia"},{"key":"25469_CR26","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/leu.2017.345","volume":"32","author":"F Maura","year":"2018","unstructured":"Maura, F. et al. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. Leukemia 32, 1043\u20131047 (2018).","journal-title":"Leukemia"},{"key":"25469_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0221-9","volume":"9","author":"PH Hoang","year":"2019","unstructured":"Hoang, P. H., Cornish, A. J., Dobbins, S. E., Kaiser, M. & Houlston, R. S. Mutational processes contributing to the development of multiple myeloma. Blood Cancer J. 9, 60 (2019).","journal-title":"Blood Cancer J."},{"key":"25469_CR28","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94\u2013101 (2020).","journal-title":"Nature"},{"key":"25469_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11037-8","volume":"10","author":"F Maura","year":"2019","unstructured":"Maura, F. et al. A practical guide for mutational signature analysis in hematological malignancies. Nat. Commun. 10, 2969 (2019).","journal-title":"Nat. Commun."},{"key":"25469_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15740-9","volume":"11","author":"EH Rustad","year":"2020","unstructured":"Rustad, E. H. et al. Timing the initiation of multiple myeloma. Nat. Commun. 11, 1917 (2020).","journal-title":"Nat. Commun."},{"key":"25469_CR31","doi-asserted-by":"crossref","unstructured":"Samur, M. K. et al. Genome-wide somatic alterations in multiple myeloma reveal a superior outcome group. J. Clin. Oncol. 38, 3107\u20133118 (2020).","DOI":"10.1200\/JCO.20.00461"},{"key":"25469_CR32","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-019-0254-0","volume":"9","author":"TM Schmidt","year":"2019","unstructured":"Schmidt, T. M. et al. Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer J. 9, 94 (2019).","journal-title":"Blood Cancer J."},{"key":"25469_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-018-0066-6","volume":"4","author":"Z Sztupinszki","year":"2018","unstructured":"Sztupinszki, Z. et al. Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. npj Breast Cancer 4, 16 (2018).","journal-title":"npj Breast Cancer"},{"key":"25469_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09555-6","volume":"10","author":"BG Barwick","year":"2019","unstructured":"Barwick, B. G. et al. Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nat. Commun. 10, 1911 (2019).","journal-title":"Nat. Commun."},{"key":"25469_CR35","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1038\/s41375-018-0035-y","volume":"32","author":"MC Fontana","year":"2018","unstructured":"Fontana, M. C. et al. Chromothripsis in acute myeloid leukemia: biological features and impact on survival. Leukemia 32, 1609\u20131620 (2018).","journal-title":"Leukemia"},{"key":"25469_CR36","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/ijc.30778","volume":"141","author":"J Smida","year":"2017","unstructured":"Smida, J. et al. Genome-wide analysis of somatic copy number alterations and chromosomal breakages in osteosarcoma. Int. J. Cancer 141, 816\u2013828 (2017).","journal-title":"Int. J. Cancer"},{"key":"25469_CR37","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1182\/blood-2019-130335","volume":"134","author":"C Ashby","year":"2019","unstructured":"Ashby, C. et al. Chromoplexy and chromothripsis are important prognostically in myeloma and deregulate gene function by a range of mechanisms. Blood 134, 3767\u20133767 (2019).","journal-title":"Blood"},{"key":"25469_CR38","doi-asserted-by":"crossref","unstructured":"Davies, H. et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat. Med. 23, 517\u2013525 (2017).","DOI":"10.1038\/nm.4292"},{"key":"25469_CR39","doi-asserted-by":"crossref","unstructured":"Jovanovi\u0107, K. K. et al. Deregulation and targeting of TP53 pathway in multiple myeloma. Front. Oncol. 8, 665 (2019).","DOI":"10.3389\/fonc.2018.00665"},{"key":"25469_CR40","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1182\/blood.V122.21.532.532","volume":"122","author":"JJ Keats","year":"2013","unstructured":"Keats, J. J. et al. Interim analysis of the Mmrf commpass Trial, a longitudinal study in multiple myeloma relating clinical outcomes to genomic and immunophenotypic profiles. Blood 122, 532\u2013532 (2013).","journal-title":"Blood"},{"key":"25469_CR41","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1158\/1078-0432.CCR-20-2245","volume":"27","author":"F Maura","year":"2021","unstructured":"Maura, F. et al. Initial whole-genome sequencing of plasma cell neoplasms in first responders and recovery workers exposed to the World Trade Center attack of September 11, 2001. Clin. Cancer Res. 27, 2111 (2021).","journal-title":"Clin. Cancer Res."},{"key":"25469_CR42","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s42003-021-01938-0","volume":"4","author":"EH Rustad","year":"2021","unstructured":"Rustad, E. H. et al. mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignancies. Commun. Biol. 4, 424 (2021).","journal-title":"Commun. Biol."},{"key":"25469_CR43","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1093\/nar\/gkw520","volume":"44","author":"R Shen","year":"2016","unstructured":"Shen, R. & Seshan, V. E. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 44, e131 (2016).","journal-title":"Nucleic Acids Res."},{"key":"25469_CR44","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1038\/bjc.2012.451","volume":"107","author":"V Abkevich","year":"2012","unstructured":"Abkevich, V. et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br. J. Cancer 107, 1776\u20131782 (2012).","journal-title":"Br. J. Cancer"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25469-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25469-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25469-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T09:19:25Z","timestamp":1669972765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25469-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,27]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["25469"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-25469-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.11.24.395939","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,27]]},"assertion":[{"value":"6 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.L. has received research funding from: National Institutes of Health (NIH), National Cancer Institute (NCI), U.S. Food and Drug Administration (FDA), Multiple Myeloma Research Foundation (MMRF), International Myeloma Foundation (IMF), Leukemia and Lymphoma Society (LLS), Perelman Family Foundation, Rising Tide Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, Karyopharm; Honoraria\/ad boards: Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno, Pfizer; and serves on Independent Data Monitoring Committees (IDMCs) for clinical trials lead by Takeda, Merck, Janssen, Theradex. All other authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5172"}}